Medical devices, healthcare technology and the business of care
PMA SUPPLEMENT · P200015/S083

Edwards Crimper (9600LDS20, 9600LDS23, 9600LDS26, 9600LDS29)

Edwards Lifesciences, LLC · Decision date Sep 23, 2026

FDA DECISIONP200015/S083

What did the FDA decide?

FDA records P200015/S083 as a supplement to PMA P200015, with the supplement type “30-Day Notice”. The recorded decision is OK30 (30-day notice), dated Sep 23, 2026.

FDA approval order statement

adoption of the Edwards Crimper into an existing validated sterilization cycle
Regulatory pathway
PMA supplement
Supplement type
30-Day Notice
Clinical specialty
Cardiovascular
Decision date
Sep 23, 2026
FDA change category
Process Change - Manufacturer/Sterilizer/Packager/Supplier

FDA source record

Regulatory record facts

Identifier
P200015/S083
Regulatory pathway
PMA supplement
Product code
NPV
Decision code
OK30
Decision date
Sep 23, 2026
Source update
Nov 9, 2026
Original record
Open FDA source record

About this medical device

FDA device category: Pulmonary valve prosthesis percutaneously delivered.

Product code
NPV
FDA device class
f

For the original device and its historical approval scope, see PMA P200015. Subsequent supplements may change the device or its indications.

FDA decision timeline

  1. P200015 · Original PMA

    Edwards SAPIEN 3 Transcatheter Heart Valve System with Edwards Commander Delivery System

  2. P200015/S083 received

    Application receipt date recorded by FDA.

  3. P200015/S083 · FDA decision

    30-Day Notice

  4. P200015/S077 · Related supplement

    SAPIEN 3 Transcatheter Pulmonary Valve System with Alterra C Adaptive Prestent

  5. P200015/S084 · Related supplement

    Edwards SAPIEN 3 Transcatheter Heart Valve (9600TFX)

Timeline entries are records held by MedtechLedger for P200015. View FDA’s full supplement list.

Related devices and submissions

Same PMA: P200015

Explore the linked device profile

Other records with product code NPV

Product / regulatory recordCompanyPathwayDecision dateSource
Harmony TPV SystemP200046/S052
Medtronic, Inc.PMA supplementSep 30, 2026FDA
Medtronic, Inc.PMA approvalMar 26, 2021FDA

A shared product code identifies a classification relationship; it does not establish clinical equivalence.

Regulatory context

A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.

Read our guide to FDA clearance and approval · FDA’s explanation of this pathway

Manufacturer intelligence

Edwards Lifesciences, LLC

Headquarters
Not reported
Brand website
Not reported
FDA applicant address
One Edwards Way, Irvine, CA, 92614

Sources and methodology

FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.

How we use FDA records